As New Zealand nears the toughest part of its Covid-19 vaccination drive, it's been suggested the Pfizer shot could be offered to children younger than 12 by the end of the year. University of Auckland epidemiologist and data scientist Dr Janine Paynter discusses what that means.
Where are trials currently at with Covid-19 vaccines and children under 12, and what's the evidence telling us so far?
Already, there's an early subset of results available for trials that have been investigating the safety and effectiveness of the Cominarty or Pfizer vaccine for children in different age groups. Around 4500 children aged between six months and 11 years have been participating in them - but only the results for 2268 children, aged five to 11 years, are available at this stage. These are children from the United States, Finland, Poland and Spain. So far, the trial shows that Cominarty is safe and effective for five-to-11-year-olds, and these results are comparable with results for older children and young adults.
Assuming the vaccine is soon approved for use in New Zealand for kids under 12, how will we know it's safe?